Triptorelin: Trelstar/Decapeptyl, hormone-shutdown drug for prostate cancer & early puberty
FDA-approved injectable drug that shuts down sex-hormone production to slow prostate cancer growth or halt early-onset puberty in children.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Triptorelin is an injectable medication that shuts down the body's production of sex hormones — testosterone in men, estrogen in women. It works by mimicking the brain's own hormone-releasing signal so relentlessly that the pituitary eventually stops responding to it. That sustained shutdown is what makes it useful in hormone-driven cancers and in conditions where puberty is starting too early. In the United States it is FDA-approved as Trelstar for advanced prostate cancer (first approved June 2000) and as Triptodur for central precocious puberty in children aged 2 and older (June 2017). Outside the US it is sold as Decapeptyl, Diphereline, Gonapeptyl, Pamorelin, and others, with approvals extending to endometriosis, uterine fibroids, IVF pituitary-suppression protocols, and adjuvant ovarian suppression in premenopausal breast cancer.
The stored sequence HWSYDWLRPG is the ten-amino-acid backbone; in the actual drug molecule the N-terminus is cyclised to pyroglutamate, position 6 carries a D-tryptophan instead of the natural L-tryptophan, and the C-terminus is capped with an amide — none of which appear in the stored single-letter string but together account for the peptide's high receptor potency and resistance to enzymatic breakdown.
Triptorelin's clinical efficacy is considered essentially equivalent to leuprolide and goserelin within the GnRH agonist class; selection between them is driven by formulation availability, depot interval, payer access, and prescriber preference rather than meaningful efficacy differences (Schally and colleagues, npj Aging 2025; Kawahara and colleagues, Cureus 2025).
History
Triptorelin emerged from GnRH analog research in the late 1970s and early 1980s that followed Andrew Schally's Nobel Prize–winning characterisation of native luteinizing hormone-releasing hormone (LHRH) in 1977. The D-tryptophan at position 6 — a strategy for substituting a D-amino acid at the cleavage-sensitive sixth residue — conferred substantially enhanced receptor binding and metabolic stability, placing triptorelin among the most potent GnRH superagonists of the era. European pharmaceutical partners including Beaufour-Ipsen and Ferring brought it to market as Decapeptyl for prostate cancer and endometriosis in the late 1980s. In the United States, triptorelin pamoate (Trelstar) was developed and received FDA approval in June 2000 for advanced prostate cancer, entering a market already established by leuprolide. The longer-interval 6-month depot Triptodur received FDA approval in June 2017 for central precocious puberty, offering a less-frequent injection schedule compared with monthly leuprolide depot.
What it does
Triptorelin works in two distinct phases. When first given, it triggers a brief surge in LH and FSH — and consequently in testosterone or estrogen — because it is stimulating GnRH receptors more powerfully than the body's own hormone does. This initial "flare" lasts roughly one to two weeks. With continuous exposure from a depot injection, however, the pituitary's GnRH receptors become overwhelmed and effectively switch off, stopping LH and FSH release and collapsing sex-hormone production to castrate levels. That sustained suppression phase is the therapeutic goal.
For prostate cancer, eliminating testosterone starves the tumour of the hormonal signal it depends on — androgen deprivation therapy (ADT). For central precocious puberty, suppressing LH and FSH halts premature breast development, testicular growth, or menstruation and slows the accelerated bone-age advancement that would otherwise compromise adult height. For endometriosis and uterine fibroids (approved internationally), estrogen withdrawal reduces lesion growth and symptoms. For IVF protocols, controlled pituitary suppression prevents a premature LH surge before egg retrieval.
Evidence
- Human: FDA-approved for advanced prostate cancer and central precocious puberty on the basis of Phase 3/4 randomised controlled trial data. The PRIORITI Phase 4 RCT studied triptorelin versus active surveillance in high-risk prostate cancer (Szmulewitz and colleagues 2024). The GETUG 14 Phase 3 RCT established short-term ADT with high-dose radiotherapy in intermediate- and high-risk localised prostate cancer (Hennequin and colleagues 2025). The TALISMAN real-world French cohort examined triptorelin in aggressive prostate cancer clinical practice (Brureau and colleagues 2025). A Phase 3 RCT evaluated two formulations of triptorelin in Chinese patients with endometriosis (Li and colleagues, Advances in Therapy 2022). A Phase 3 open-label trial assessed the 3-month triptorelin formulation in Chinese children with central precocious puberty (Luo and colleagues, Archives of Toxicology 2023). A prospective RCT compared triptorelin with leuprolide acetate in IVF long-protocol cycles (Demirol and Gurgan 2003). A systematic review and meta-analysis examined triptorelin for lower urinary tract symptoms in prostate cancer patients (Wen and colleagues 2024). A meta-analysis examined GnRH antagonist versus GnRH agonist cardiovascular effects in prostate cancer (Dong and colleagues, Frontiers in Endocrinology 2023). Post-ADT testosterone recovery kinetics were characterised in a clinical trial (van Dijk and colleagues 2021). A pharmacovigilance analysis of triptorelin adverse events used FDA FAERS data from January 2004 to September 2024 (Scientific Reports 2025).
- Animal: GnRH receptor desensitisation and HPG axis suppression are thoroughly characterised in rodent and primate models; triptorelin's receptor specificity for GnRHR1 (distinct from GnRHR2) has been confirmed in comparative receptor-binding work (reviewed in Millar and colleagues, Frontiers in Endocrinology 2017).
- In vitro: Receptor pharmacology, phospholipase C uncoupling, and transcriptional downregulation of GnRHR expression are well-established; D-amino acid substitution effects on receptor binding and metabolic stability are well-characterised.
Known effects
- Testosterone suppression to castrate levels (advanced prostate cancer) — FDA-approved; Phase 3/4 RCT evidence (PRIORITI, GETUG 14, TALISMAN)
- Suppression of precocious puberty (central precocious puberty, paediatric) — FDA-approved; Phase 3 trial evidence
- Endometriosis symptom relief and post-surgical recurrence prevention — Approved internationally (EU and others); Phase 3 RCT evidence
- IVF pituitary suppression (controlled ovarian stimulation) — Clinical use supported by comparative RCT
- Single-dose HPG-axis restart after anabolic steroid use (off-label PCT) — No controlled trial support; community use only; see Myths section
Myths and misconceptions
"Triptorelin and leuprolide work by different mechanisms — one is an agonist, the other an antagonist." Both are GnRH agonists that exploit the same pituitary desensitisation mechanism. They differ in their position-6 amino acid substitution (D-tryptophan for triptorelin, D-leucine for leuprolide) and in their available depot intervals, but their pharmacological class and clinical efficacy are essentially equivalent. The GnRH antagonists — degarelix (injectable) and relugolix (oral) — are a genuinely distinct class that blocks GnRH receptors without an initial flare.
"A single small dose of triptorelin can safely restart natural testosterone after anabolic steroid use." This bodybuilding-community claim has no controlled clinical trial support. The pharmacological logic — that a brief GnRH pulse triggers an LH/FSH surge without crossing into the desensitisation window — has not been validated in human trial data. Even a single dose can produce prolonged HPG-axis suppression rather than the intended brief restart. The dose-response relationship in this context is unpredictable, and the available controlled evidence does not support this use.
"The testosterone flare when starting triptorelin means the drug isn't working." The flare is the expected pharmacology: initial GnRH receptor stimulation produces transient LH/FSH and gonadal hormone elevation before pituitary desensitisation develops over two to four weeks. It is precisely why anti-androgen cover is standard practice in high-tumour-burden prostate cancer. Sustained suppression after the desensitisation phase is the intended outcome.
"Triptorelin causes permanent infertility." GnRH agonist effects are reversible in most patients. Testosterone recovery after androgen deprivation therapy typically takes 6–12 months and can be incomplete in older men after extended treatment (van Dijk and colleagues 2021). In premenopausal women treated for endometriosis or ovarian suppression, fertility generally returns after discontinuation.
"Triptorelin is safer than leuprolide because it has fewer side effects." Both agents share essentially identical class-level adverse effects and no adequately powered head-to-head safety comparison exists. Selection between them is typically driven by formulation availability and clinical context rather than any established safety advantage for either.
Safety signals
- Hot flashes — Most commonly reported class effect across approved indications; documented in FDA label and Phase 3 trials
- Erectile dysfunction and decreased libido — Expected consequence of castrate-level testosterone suppression; documented in FDA label and clinical use
- Testicular atrophy — Expected with sustained testosterone suppression
- Bone mineral density loss — Principal long-term complication with extended ADT; proactive bone-protection co-management is appropriate in at-risk patients; documented in FDA label and clinical use
- Cardiovascular and metabolic risk — Increased risk of cardiovascular events, diabetes, and dyslipidaemia associated with GnRH agonist ADT; class-level signal; triptorelin-specific cardiovascular comparison data are more limited than for leuprolide; reviewed in meta-analysis (Dong and colleagues, Frontiers in Endocrinology 2023)
- Initial testosterone/estrogen flare — First 7–14 days after depot injection; can worsen prostate cancer symptoms (especially bone metastases or spinal cord compression); anti-androgen pre-loading is standard practice in high-tumour-burden patients; documented in FDA label
- Injection site reactions — Reported across depot formulations in FDA label
- QT interval prolongation — GnRH agonists are associated with QT prolongation; ECG and electrolyte monitoring is relevant in at-risk patients
- Testosterone recovery — potentially incomplete — After extended ADT, recovery can be slow and incomplete in some older men (van Dijk and colleagues 2021); per available sources, somewhat slower recovery after triptorelin compared with the GnRH antagonist relugolix in HERO trial sub-analyses
- Fetal harm — Label contraindication; effective contraception required for women of reproductive potential during therapy and after discontinuation
- Hypersensitivity — Cross-reactivity with other GnRH analogs is possible; documented in FDA label
- Off-label PCT use — No formal safety data for single-dose use in otherwise healthy men; risk of inadvertent prolonged HPG-axis suppression is real and unquantified
Regulatory status
- US (FDA): Prescription-only. Trelstar (triptorelin pamoate) approved June 2000 for advanced prostate cancer; Triptodur (triptorelin acetate) approved June 2017 for central precocious puberty in paediatric patients aged 2 and older. Not approved in the US for endometriosis, uterine fibroids, IVF protocols, breast cancer ovarian suppression, or post-cycle therapy.
- EU / International: Approved as Decapeptyl (Ipsen/Ferring), Diphereline, Gonapeptyl, Pamorelin, and other brand names across major markets. International approvals include prostate cancer, endometriosis, uterine fibroids, central precocious puberty, female infertility (IVF), and adjuvant ovarian suppression in premenopausal breast cancer; specific current EMA authorisation details not individually verified in this card.
- WADA: Per available sources, triptorelin is prohibited under S4 Hormone and Metabolic Modulators on the WADA Prohibited List; prohibited for male athletes in and out of competition; the prohibition specifically captures PCT use following anabolic-androgenic steroid administration; therapeutic use exemption applies for approved oncology or paediatric indications.
Mechanism
Triptorelin acts at the GnRH receptor (GnRHR), a Gq/11-coupled GPCR expressed on anterior-pituitary gonadotrophs. The D-tryptophan at position 6 increases receptor binding affinity and confers resistance to peptidase degradation, while the pyroglutamate at the N-terminus and the C-terminal amide further protect the peptide from aminopeptidase and carboxypeptidase cleavage. Together these modifications make triptorelin 13-fold more potent than native GnRH for LH release and 21-fold more potent for FSH release, and extend its plasma half-life from minutes (native GnRH) to approximately 3 hours for the immediate-release form.
Acute phase (flare): GnRH receptor engagement activates phospholipase C through Gq/11 coupling, generating IP3 and DAG, which drive calcium mobilisation and PKC activation. The result is robust LH and FSH secretion, with consequent gonadal testosterone or estrogen elevation over the first 7–14 days.
Sustained phase (desensitisation): Continuous receptor stimulation from depot formulations drives receptor internalisation, uncoupling from phospholipase C signalling, and transcriptional downregulation of GnRHR expression. LH and FSH output collapses, and gonadal sex-steroid production falls to castrate levels — testosterone below 50 ng/dL in 3–4 weeks. The absence of a cytoplasmic tail on human GnRHR1 (in contrast to primate GnRHR2, which fully desensitises within 60 minutes) means that human receptor desensitisation is somewhat slower and driven primarily by transcriptional downregulation rather than rapid internalisation (Millar and colleagues, Frontiers in Endocrinology 2017).
Depot delivery: PLGA (poly-lactic-co-glycolic acid) microsphere technology provides sustained triptorelin release over 1, 3, or 6 months depending on formulation. Triptorelin pamoate (Trelstar) and triptorelin acetate (Triptodur) are the principal salt forms used in the approved depot preparations.
The off-label single-dose PCT hypothesis exploits the flare phase: a brief GnRH pulse aims to trigger an LH/FSH surge sufficient to restart endogenous testosterone without crossing into the desensitisation window. The available literature notes that the dose and timing required to achieve this without inadvertent prolonged suppression have not been validated in controlled human trials.
Open questions
- Head-to-head triptorelin vs. leuprolide comparative outcomes: Most class-level evidence treats both agents as interchangeable. Adequately powered head-to-head trials examining testosterone suppression onset, cardiovascular safety, and quality-of-life endpoints are limited.
- GnRH agonist vs. antagonist selection in cardiovascular-risk patients: The PRONOUNCE trial (degarelix vs. leuprolide) was inconclusive, and triptorelin-specific data in high-cardiovascular-risk patients are limited. Optimal class selection in this subgroup remains debated.
- Single-dose PCT safety and efficacy: No controlled trials, no formal safety data, and no head-to-head comparison with HCG + SERM for this off-label application.
- Optimal duration of ovarian suppression in premenopausal breast cancer: International guidelines recommend GnRH agonists for selected high-risk premenopausal women receiving tamoxifen or aromatase inhibitors, but optimal duration and patient-selection refinement are ongoing.
- Paediatric long-term outcomes after central precocious puberty treatment: Effects on adult height, bone density, fertility, and metabolic health following childhood GnRH agonist courses are being characterised in registry data.
- Sequencing with novel anti-androgens in prostate cancer: The EMBARK trial established enzalutamide combination data; further sequencing questions with apalutamide, darolutamide, and other agents are evolving.
Related peptides
- Leuprolide — The closest clinical comparator: a GnRH agonist with D-leucine at position 6 instead of D-tryptophan. Both agents achieve equivalent pituitary desensitisation and castrate-level testosterone suppression; the main differences are formulation options and depot intervals.
- Gonadorelin — The natural, unmodified GnRH decapeptide that triptorelin is designed to mimic. Where triptorelin's D-amino acid modifications make it a long-acting superagonist, gonadorelin's short half-life and pulsatile administration are used diagnostically or to stimulate gonadotropin release.
- Kisspeptin — An upstream regulator of GnRH neurons in the hypothalamus; kisspeptin signalling at KISS1R drives GnRH release, placing it one step above the GnRH/triptorelin axis in the HPG hierarchy.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.6974490284919739 | boltz-2 |
| ranking score | 0.7061840891838074 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.327 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10602,
sequence = {HWSYDWLRPG},
target = {lhcgr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}